文献速递腹部CTMR

LI-RADS非放疗治疗反应算法v2024:肝胆期MRI与CT诊断HCC活性比较

Evaluating Accuracy of LI-RADS Nonradiation Treatment Response Algorithm v2024 and Ancillary Features at Hepatobiliary MRI versus CT.
PubMed 文献 · Radiology · 2026-01-01

本研究回顾性纳入245例肝细胞癌非放疗局部区域治疗后接受肝胆期MRI(部分联合CT)并手术的患者,比较LI-RADS非放疗TRA v2024与v2017的诊断效能。结果发现v2024联合辅助征象时敏感度(79.3%)和准确率(81.6%)最高,且肝胆期MRI优于CT。

要点

  • LI-RADS非放疗TRA v2024联合辅助征象可提高HCC活性检出敏感度与准确率,特异性未显著下降。
  • 肝胆期MRI诊断HCC活性优于CT,尤其在TACE术后。
  • 消融术后肝胆期MRI与CT诊断准确率相当,选择检查时需结合临床场景。

核心结论

  • LI-RADS非放疗TRA v2024联合辅助征象检测非放疗局部区域治疗后存活HCC的敏感度和准确率优于v2017,且未牺牲特异性。
  • 肝胆期MRI在检测HCC活性方面敏感度和准确率高于CT,该优势在TACE术后显著,消融术后无差异。

研究设计与样本

  • 三名放射科医师独立应用LI-RADS非放疗TRA v2024(含与不含辅助征象)及v2017评估最大治疗病灶并共识,参考标准为手术病理坏死程度。
  • 诊断效能比较采用Bonferroni校正McNemar检验,观察者间一致性采用Fleiss κ。

关键影像表现/征象

  • 影像评估对象为局部区域治疗后最大治疗病灶的HCC活性,依据LI-RADS非放疗TRA分类标准判读。

诊断标准与关键数值

  • 肝胆期MRI中,LI-RADS非放疗TRA v2024联合辅助征象诊断敏感度79.3%、准确率81.6%,高于v2024不含辅助征象(敏感度65.8%、准确率71.8%)和v2017(敏感度67.4%、准确率73.1%),均P<.001。
  • v2024联合辅助征象与v2024不含辅助征象、v2017相比特异性差异均无统计学意义(P=.47)。
  • 194例同时接受CT与MRI患者中,肝胆期MRI v2024联合辅助征象敏感度78.7%、准确率81.4%,CT敏感度64.0%、准确率70.6%,差异均有统计学意义(P=.001和P=.002)。
  • 肝胆期MRI与CT特异性对比为90.9%与93.2%,无统计学差异(P>.99)。
  • 肝胆期MRI准确率在TACE术后高于CT(82.7% vs 66.1%,P<.001),消融术后两者准确率均为79.1%(53/67),无统计学差异(P>.99)。

临床应用与阅片要点

  • 阅片评估HCC非放疗局部区域治疗后活性时优先采用LI-RADS非放疗TRA v2024并联合辅助征象,以提高活性检出敏感度。
  • TACE术后评估HCC活性时肝胆期MRI优于CT,条件允许应优先选择肝胆期MRI。
  • 消融术后肝胆期MRI与CT准确率相当,阅片时可结合设备可及性及患者因素选择检查方式。

局限性

  • 本研究为回顾性单中心设计,存在选择偏倚可能。
  • 仅评估最大治疗病灶,未涉及多发病灶的全面评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Liver Imaging Reporting and Data System (LI-RADS) Nonradiation Treatment Response Algorithm (TRA) version 2024 (v2024) was recently introduced following version 2017 (v2017) to standardize the assessment of hepatocellular carcinoma (HCC) after nonradiation local-regional therapy (LRT). However, a comparison of their accuracy across imaging modalities has not yet been performed. Purpose To compare the diagnostic accuracy of LI-RADS Nonradiation TRA v2024 with that of LI-RADS TRA v2017 for assessing HCC viability after LRT and to evaluate the incremental value of ancillary features (AFs) and accuracy of CT versus hepatobiliary agent (HBA)-enhanced MRI. Materials and Methods This retrospective study included patients who underwent nonradiation LRT for HCC followed by HBA MRI, or HBA MRI and CT, and then hepatic surgery between January 2018 and December 2021. Three radiologists independently applied LI-RADS Nonradiation TRA v2024 (with and without AFs) and v2017 to the largest treated lesion and reached a consensus. Surgical pathologic findings (incomplete or complete necrosis) were the reference standard. Diagnostic accuracy metrics were compared with Bonferroni-adjusted McNemar tests; interobserver agreement was assessed with Fleiss κ. Results This study included 245 patients (mean age, 60 years ± 9.3 [SD]; 199 men). At HBA MRI, LI-RADS Nonradiation TRA v2024 with AFs demonstrated the highest diagnostic sensitivity (79.3%) and accuracy (81.6%), compared with v2024 without AFs (sensitivity, 65.8%; accuracy, 71.8%) and v2017 (sensitivity, 67.4%; accuracy, 73.1%) (all P < .001) and preserved specificity (both P = .47). Among 194 patients who underwent both CT and MRI, HBA MRI (v2024 with AFs) achieved higher sensitivity (78.7%) and accuracy (81.4%) than CT (64.0% and 70.6%, respectively; P = .001 and P = .002, respectively), with no evidence of a difference in specificity (90.9% vs 93.2%; P > .99). HBA MRI showed higher accuracy than CT after transarterial chemoembolization (82.7% vs 66.1%; P < .001) but not after ablation (both 79.1% [53 of 67 patients]; P > .99). Conclusion LI-RADS Nonradiation TRA v2024, particularly when AFs were incorporated, improved sensitivity and accuracy for detecting viable HCC after nonradiation LRT compared with v2017, and HBA MRI showed higher sensitivity and accuracy over CT. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Kang in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Shin, Yoo, Gu, et al. Evaluating Accuracy of LI-RADS Nonradiation Treatment Response Algorithm v2024 and Ancillary Features at Hepatobiliary MRI versus CT. Radiology. 2026. PMID: 42227857. doi:10.1148/radiol.253143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。